Navient Corp (NAVI) Given Average Rating of “Hold” by Analysts

Shares of Navient Corp (NASDAQ:NAVI) have received a consensus rating of “Hold” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $16.72.

A number of analysts recently issued reports on the stock. BidaskClub upgraded shares of Navient from a “strong sell” rating to a “sell” rating in a research note on Friday, March 9th. Zacks Investment Research lowered shares of Navient from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. ValuEngine lowered shares of Navient from a “hold” rating to a “sell” rating in a research note on Tuesday, June 12th. Wedbush upgraded shares of Navient from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $14.50 to $15.75 in a research note on Friday, June 1st. Finally, Compass Point upgraded shares of Navient from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Wednesday, April 4th.

Get Navient alerts:

Hedge funds have recently added to or reduced their stakes in the business. Nomura Asset Management Co. Ltd. bought a new stake in Navient during the first quarter valued at $138,000. Stone Ridge Asset Management LLC bought a new stake in Navient during the fourth quarter valued at $141,000. First Allied Advisory Services Inc. bought a new stake in Navient during the fourth quarter valued at $148,000. Gotham Asset Management LLC bought a new stake in Navient during the fourth quarter valued at $154,000. Finally, Amundi Pioneer Asset Management Inc. bought a new stake in Navient during the fourth quarter valued at $155,000. Hedge funds and other institutional investors own 98.14% of the company’s stock.

Navient opened at $13.38 on Monday, according to Marketbeat Ratings. The company has a current ratio of 21.07, a quick ratio of 21.07 and a debt-to-equity ratio of 28.03. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of 7.47, a PEG ratio of 1.19 and a beta of 2.20. Navient has a twelve month low of $11.48 and a twelve month high of $16.97.

Navient (NASDAQ:NAVI) last issued its quarterly earnings results on Tuesday, April 24th. The credit services provider reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.02. The business had revenue of $329.00 million during the quarter, compared to analyst estimates of $313.00 million. Navient had a net margin of 6.43% and a return on equity of 13.91%. During the same quarter in the previous year, the firm earned $0.37 earnings per share. analysts predict that Navient will post 1.88 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 15th. Shareholders of record on Friday, June 1st were paid a dividend of $0.16 per share. The ex-dividend date was Thursday, May 31st. This represents a $0.64 annualized dividend and a yield of 4.78%. Navient’s payout ratio is 35.75%.

About Navient

Navient Corporation provides asset management and business processing services to education, health care, and government clients at the federal, state, and local levels in the United States. The company operates in three segments: Federal Family Education Loan Program (FFELP) Loans, Private Education Loans, and Business Services.

Valeant Pharmaceuticals Intl (VRX) Stock Rating Lowered by TD Securities

TD Securities cut shares of Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) from a buy rating to a hold rating in a research note published on Friday morning, Marketbeat.com reports. The brokerage currently has $24.00 target price on the specialty pharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Cantor Fitzgerald set a $25.00 price objective on Valeant Pharmaceuticals Intl and gave the stock a buy rating in a research note on Wednesday, February 28th. Deutsche Bank raised Valeant Pharmaceuticals Intl from a hold rating to a buy rating and set a $18.00 price target for the company in a research report on Monday, March 5th. Jefferies Financial Group increased their price target on Valeant Pharmaceuticals Intl to $23.00 and gave the company a buy rating in a research report on Wednesday, May 9th. Mizuho raised Valeant Pharmaceuticals Intl from a neutral rating to a buy rating in a research report on Tuesday, May 15th. Finally, TheStreet downgraded Valeant Pharmaceuticals Intl from a c rating to a d+ rating in a research report on Friday, May 25th. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $20.54.

Get Valeant Pharmaceuticals Intl alerts:

Shares of Valeant Pharmaceuticals Intl opened at $24.27 on Friday, Marketbeat.com reports. The company has a market capitalization of $8.63 billion, a PE ratio of 6.34, a P/E/G ratio of 0.37 and a beta of -0.34. Valeant Pharmaceuticals Intl has a 52 week low of $10.94 and a 52 week high of $27.79. The company has a debt-to-equity ratio of 5.59, a current ratio of 1.18 and a quick ratio of 0.92.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.60 by $0.29. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.95 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 27.87% and a negative net margin of 10.65%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.79 earnings per share. equities research analysts predict that Valeant Pharmaceuticals Intl will post 3.33 earnings per share for the current fiscal year.

In other news, Director Schutter Richard U. De acquired 15,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Tuesday, May 15th. The stock was acquired at an average cost of $21.83 per share, with a total value of $327,450.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.87% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. First Allied Advisory Services Inc. boosted its holdings in shares of Valeant Pharmaceuticals Intl by 33.6% in the first quarter. First Allied Advisory Services Inc. now owns 15,101 shares of the specialty pharmaceutical company’s stock worth $242,000 after acquiring an additional 3,800 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Valeant Pharmaceuticals Intl by 189.4% in the first quarter. Envestnet Asset Management Inc. now owns 5,991 shares of the specialty pharmaceutical company’s stock worth $103,000 after acquiring an additional 3,921 shares during the period. Gabelli Funds LLC boosted its holdings in shares of Valeant Pharmaceuticals Intl by 3.5% in the first quarter. Gabelli Funds LLC now owns 117,088 shares of the specialty pharmaceutical company’s stock worth $1,864,000 after acquiring an additional 4,000 shares during the period. MML Investors Services LLC boosted its holdings in shares of Valeant Pharmaceuticals Intl by 15.5% in the fourth quarter. MML Investors Services LLC now owns 40,581 shares of the specialty pharmaceutical company’s stock worth $843,000 after acquiring an additional 5,431 shares during the period. Finally, Prime Capital Investment Advisors LLC bought a new position in shares of Valeant Pharmaceuticals Intl in the fourth quarter worth $142,000. 46.95% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Sei Investments Co. Purchases 40,219 Shares of Cabot Corp (CBT)

Sei Investments Co. increased its position in shares of Cabot Corp (NYSE:CBT) by 137.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,527 shares of the specialty chemicals company’s stock after acquiring an additional 40,219 shares during the quarter. Sei Investments Co. owned approximately 0.11% of Cabot worth $3,874,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Citizens Financial Group Inc RI acquired a new position in shares of Cabot during the 4th quarter valued at about $142,000. Quadrature Capital Ltd acquired a new position in shares of Cabot during the 4th quarter valued at about $219,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Cabot by 48.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,663 shares of the specialty chemicals company’s stock valued at $226,000 after acquiring an additional 1,194 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Cabot during the 1st quarter valued at about $247,000. Finally, Quantbot Technologies LP acquired a new position in Cabot in the first quarter valued at about $252,000. 85.56% of the stock is currently owned by hedge funds and other institutional investors.

Get Cabot alerts:

A number of research analysts have commented on CBT shares. ValuEngine cut shares of Cabot from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Loop Capital set a $80.00 target price on shares of Cabot and gave the company a “buy” rating in a research report on Monday, April 23rd. Robert W. Baird reaffirmed a “hold” rating and issued a $67.00 target price on shares of Cabot in a research report on Tuesday, April 17th. Zacks Investment Research raised shares of Cabot from a “hold” rating to a “buy” rating and set a $69.00 target price on the stock in a research report on Thursday, May 10th. Finally, TheStreet cut shares of Cabot from a “b-” rating to a “c” rating in a research report on Monday, May 7th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Cabot has an average rating of “Buy” and an average target price of $72.00.

In other news, SVP Brian A. Berube sold 7,311 shares of the stock in a transaction dated Thursday, May 31st. The shares were sold at an average price of $60.30, for a total transaction of $440,853.30. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gottberg Friedrich Von sold 10,000 shares of the stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $61.23, for a total transaction of $612,300.00. Following the sale, the insider now directly owns 29,854 shares in the company, valued at approximately $1,827,960.42. The disclosure for this sale can be found here. Insiders have sold 228,901 shares of company stock worth $14,194,838 in the last three months. Corporate insiders own 2.20% of the company’s stock.

NYSE CBT opened at $63.33 on Tuesday. Cabot Corp has a 12 month low of $50.56 and a 12 month high of $68.63. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.07 and a current ratio of 1.67. The stock has a market capitalization of $3.95 billion, a price-to-earnings ratio of 18.46, a P/E/G ratio of 1.50 and a beta of 1.38.

Cabot (NYSE:CBT) last issued its quarterly earnings results on Monday, May 7th. The specialty chemicals company reported $1.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.00 by $0.04. The business had revenue of $818.00 million for the quarter, compared to analysts’ expectations of $746.30 million. Cabot had a negative net margin of 6.14% and a positive return on equity of 15.83%. The business’s quarterly revenue was up 20.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.87 earnings per share. analysts predict that Cabot Corp will post 4.11 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 8th. Stockholders of record on Friday, May 25th were given a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a dividend yield of 2.08%. The ex-dividend date was Thursday, May 24th. This is a boost from Cabot’s previous quarterly dividend of $0.32. Cabot’s dividend payout ratio is currently 38.48%.

About Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company offers carbon black, a form of elemental carbon used to enhance the physical properties of the systems and applications in which it is incorporated; and rubber blacks for use as a rubber reinforcing agent and performance additive in tires, hoses, belts, extruded profiles, and molded goods.